Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test catch hidden diabetes in late pregnancy?

NCT ID NCT07776314

Prevention Sponsor: Izmir Ataturk Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial asks whether screening pregnant women for gestational diabetes at 32-34 weeks—later than usual—can improve outcomes. Women who previously tested negative or were never screened will get a fasting blood glucose test. The study will track complications like NICU admissions, large babies, and high blood pressure to see if later screening helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fasting blood glucose screening test
What this could lead to
If screening catches late-onset gestational diabetes, it could lead to earlier treatment and fewer complications for mothers and babies.
What could go wrong
The trial is small and early, and the benefits of screening are not yet proven. False positives could cause unnecessary worry or interventions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of pregnant women aged 18 to 45 years with confirmed singleton pregnancies between 32+0 and 34+6 weeks of gestation, presenting for routine antenatal care at the Obstetrics and Gynecology Outpatient Clinic of izmir katip çelebi atatürk Training and Research . Participants are selected from low-to-moderate risk antenatal admissions and will be followed prospectively through labor, delivery, and the postpartum/neonatal period to assess maternal and perinatal outcomes.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gestational Age: Confirmed singleton pregnancy between 32+0 and 34+6 weeks of gestation based on the last menstrual period (LMP) and/or first-trimester crown-rump length (CRL) ultrasound measurement. Follow-up: Intention and willingness to deliver at the study hospital and complete all planned follow-up visits until the end of the postpartum period. Informed Consent: Voluntary agreement to participate in the study evidenced by signed written informed consent. Exclusion Criteria: * Multifetal pregnancies (e.g., twins, triplets) Fetal Anomalies Pre-gestational Chronic Diseases Protocol Non-compliance / Loss to Follow-up Preterm Birth / Preterm Labor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pregnancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gestational diabetes Pregnancy in Diabetics

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnancy Pregnancy in diabetes Pregnancy outcomes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • İzmir Katip Çelebi Atatürk Training and Research

    RECRUITING

    Izmir, Karabağlar, 35360, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.